NCT00293904

Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy

Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Cytos Biotechnology AG · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether the use of a specific immunomodulatory principle (QbG10) together with conventional grass pollen allergen leads to a more rapid and more pronounced decrease of sensitivity against pollen than with the grass pollen allergen alone

Conditions

• Hypersensitivity

Interventions

Type	Name	Description
BIOLOGICAL	CYT005-AllQbG10

Timeline

• Start date: 2006-02-01
• Completion: 2007-02-01
• First posted: 2006-02-20
• Last updated: 2007-09-20

Locations

1 site across 1 country: Switzerland